SMYD3 and prostate cancer: These SMYD3-mediated methylation events have been observed in prostate cancer cell lines (Vieira et al., 2015) and in in vitro assays using histones from HeLa cells (Foreman et al., 2011); however, H4K20me3 was not shown to be a substrate of SMYD3 in other cell line tested, including MEFs, HeLa, and MCF7 cells (van Aller et al., 2012).